Abbott releases data for “potentially effective and safe” ADHD treatment

New data from phase two trials of Abbott’s neuronal nicotinic receptor (NNR) agonist ABT-089 shows that it is a “potentially effective and safe” treatment for adults suffering with Attention Deficit Hyperactivity Disorder (ADHD), the company has announced.

According to the firm, the study found that ABT-089 “appears to significantly improve” key ADHD symptoms while increasing a patient’s quality of life, effectiveness at work and overall impairment.

The tests also indicated that tolerance of the drug is generally good, with no significantly detrimental effects on sleep, appetite, heart rate or blood pressure.

Abbott said the test demonstrate the potential for using ABT-089 as an alternative to existing ADHD treatments, many of which have negative side effects on patients’ vital signs.

The company’s divisional vice-president for neuroscience discovery James Sullivan PhD said: “We are very encouraged with the results of our ADHD work; this is a condition that demands innovative treatments, particularly to address side effect issues that have been observed with current treatments.”

Although ADHD is primarily associated with early childhood, the disorder persists into adulthood in around two-thirds of cases.

According to the National Institute of Mental Health, its principal symptoms are inattention, hyperactivity and impulsivity.